

## Special Issue

# Radiation Response Biomarkers for Individualised Cancer Treatments

### Message from the Guest Editors

It is an important and effective tool in the arsenal to treat numerous solid tumours. Improving the precision of radiotherapy has long been the quest of cancer scientists and clinicians. Biomarkers are essential for predicting and/or monitoring radiation exposure-associated effects. Ever-evolving technologies allow the detection and validation of new and emerging radiation biomarkers, whether genetic, epigenetic, cell-based, cell-free, or present in extracellular vesicles. The aim of this Special Issue is to present an insight into the ongoing state-of-the-art research in the oncology radiation response biomarker field and its applications in the ever-evolving field of personalised medicine. We welcome original scientific manuscripts (both clinical and research-based), reviews reporting novel findings in the field of radiation response, and biomarkers indicative of patient-tailored treatment and monitoring in both in vitro and in vivo systems, with a focus on research in human systems, as well as technical papers on new developments in protocols to study and validate these biomarkers.

---

### Guest Editors

Dr. Christophe Badie

Cancer Mechanisms and Biomarkers Group, Radiation Effects  
Department, Public Health England, Centre for Radiation, Chemical and  
Environmental Hazards, Chilton, Didcot, Oxon OX11 0RQ, UK


Dr. Eric Andreas Rutten

Cancer Mechanisms and Biomarkers Group, Radiation Effects  
Department, Public Health England, Centre for Radiation, Chemical and  
Environmental Hazards, Chilton, Didcot, Oxon OX11 0RQ, UK

---

### Deadline for manuscript submissions

closed (10 December 2020)



## Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 7.2  
Indexed in PubMed



[mdpi.com/si/46205](https://mdpi.com/si/46205)

*Journal of Personalized  
Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 7.2  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine* is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

---

### Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).